

Plandai Biotechnology, Inc.

57F-1 No. 7, Sec 5 Xinyi Road
Xinyi District, Taipei, City
Taiwan, ROC

886-986-386-507
avonyu@ymail.com

Quarterly Report

For the quarter ended September 30, 2025 (the “Reporting Period”)

Outstanding Shares

The number of shares outstanding of our Common Stock was:

44,889,534,371 as of September 30, 2025 (*Current Reporting Period Date or More Recent Date*)

44,889,534,371 as of June 30, 2025 (*Most Recent Completed Fiscal Year End*)

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company’s shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control⁴ of the company has occurred during this reporting period:

⁴ “Change in Control” shall mean any events resulting in:

- (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Yes:

No:

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

Jerry's, Inc. from 1942 to 2004

Diamond Ranch Foods, Inc. from 2004 to 2012

Plandai Biotechnology, Inc. from 2012 to present

Current State and Date of Incorporation or Registration: Wyoming; Date of Incorporation: November 30, 1942

Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:

Redomiciled to Wyoming from the State of Nevada on August 1, 2025 – Dissolution in Nevada on August 19, 2025.

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None.

Address of the issuer's principal executive office:

57F-1 No. 7, Sec 5 Xinyi Road

Xinyi District, Taipei, City

Taiwan, ROC

Address of the issuer's principal place of business:

Check if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No:

Yes: If Yes, provide additional details below:

2) Security Information

Transfer Agent

Name: Legacy Stock Transfer
Phone: 972-612-4120
Email: jason@signaturestocktransfer.com
Address: 16801 ADDISON ROAD – SUITE 247, ADDISON, TEXAS 75001

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	<u>PLPL</u>
Exact title and class of securities outstanding:	<u>Common</u>
CUSIP:	<u>72703D100</u>
Par or stated value:	<u>\$0.0001</u>
Total shares authorized:	<u>50,000,000,000</u> as of date: <u>September 30, 2025</u>
Total shares outstanding:	<u>44,889,534,371</u> as of date: <u>September 30, 2025</u>
Total number of shareholders of record:	<u>117</u> as of date: <u>September 30, 2025</u>

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

The authorized shares have increased to 50,000,000,000 on April 1, 2024.

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security:	Class A Preferred Stock	
Par or stated value:	\$0.0001	
Total shares authorized:	100,000	as of date: <u>September 30, 2025</u>
Total shares outstanding:	100,000	as of date: <u>September 30, 2025</u>

Total number of shareholders of record: 1 as of date: September 30, 2025

On April 1, 2024, the company increased its authorized shares to 50,000,000,000 common shares. The transfer of Preferred Series A shares was completed on June 17, 2025.

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

—

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

All shares of Common Stock shall be of junior rank to all Series A Preferred Shares.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

These Series A Preferred Shares shall not bear dividends. These Series A Preferred Shares are convertible to six hundred shares of the Company's common stock for each one share of preferred stock. These conversions can happen at any time on or after the earlier of (i) 30 days after the Issuance Date or (ii) the date that a registration statement covering the resale of Common Stock issued upon conversion of the Series A Preferred Share is declared effective by the Securities Exchange Commission (the SEC).

At every meeting of stockholders of the Company, the Series A Preferred Stock shall be entitled to voting rights equal, in aggregate, to the total number of then issued and outstanding shares eligible to vote on any manner, plus one additional vote.

In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, the holders of the Series A Preferred Shares shall be entitled to receive in cash out of the assets of the Company, whether from capital or from earnings available for distribution to its stockholders (the "Preferred Funds"), before any amount shall be paid to the holders of any of the capital stock of the Company of any class junior in rank to the Series A Preferred Shares in respect of the preferences as to the distributions and payments on the liquidation, dissolution, or winding up of the Company, an amount per Series A Preferred Shares equal to the Stated Value.

3. Describe any other material rights of common or preferred stockholders.

N/A

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

None

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.**

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes: (If yes, you must complete the table below)

Shares Outstanding <u>Opening Balance:</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date <u>June 30, 2023</u>									
Common: 8,199,034,371									
Preferred: <u>100,000</u>									
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual / Entity Shares were issued to. ***You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>11-29-23</u>	<u>Issuance</u>	<u>690,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>No</u>	<u>Congregation Pe'er Bais Yaakov</u>	<u>Settlement</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>4-4-24</u>	<u>Issuance</u>	<u>16,200,000,000</u>	<u>Common</u>	<u>0.00001</u>	<u>Yes</u>	<u>Wang, Sung-Wei</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>

<u>4-4-24</u>	<u>Issuance</u>	<u>8,100,000.00</u>	<u>Common</u>	<u>0.0000</u> <u>1</u>	<u>Yes</u>	<u>Lin, Yi-Kuan</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>4-4-24</u>	<u>Issuance</u>	<u>8,100,000.00</u>	<u>Common</u>	<u>0.0000</u> <u>1</u>	<u>Yes</u>	<u>Kuo, Sheng-Min</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>4-4-24</u>	<u>Issuance</u>	<u>360,000,000</u>	<u>Common</u>	<u>0.0000</u> <u>1</u>	<u>Yes</u>	<u>Lai, Yi-Ching</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>4-4-24</u>	<u>Issuance</u>	<u>180,000,000</u>	<u>Common</u>	<u>0.0000</u> <u>1</u>	<u>Yes</u>	<u>Liao, Chih-Yu</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>4-4-24</u>	<u>Issuance</u>	<u>180,000,000</u>	<u>Common</u>	<u>0.0000</u> <u>1</u>	<u>Yes</u>	<u>Chen, Chun-Hung</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>4-4-24</u>	<u>Issuance</u>	<u>720,000,000</u>	<u>Common</u>	<u>0.0000</u> <u>1</u>	<u>Yes</u>	<u>Liao, Pei-Hsun</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>4-4-24</u>	<u>Issuance</u>	<u>360,000,000</u>	<u>Common</u>	<u>0.0000</u> <u>1</u>	<u>Yes</u>	<u>Tsan, Li-Jo</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>4-4-24</u>	<u>Issuance</u>	<u>360,000,000</u>	<u>Common</u>	<u>0.0000</u> <u>1</u>	<u>Yes</u>	<u>Zhuo, Jiun-Jie</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>4-4-24</u>	<u>Issuance</u>	<u>360,000,000</u>	<u>Common</u>	<u>0.0000</u> <u>1</u>	<u>Yes</u>	<u>Wu, Pei-Tsang</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>4-4-24</u>	<u>Issuance</u>	<u>360,000,000</u>	<u>Common</u>	<u>0.0000</u> <u>1</u>	<u>Yes</u>	<u>Kuo, Hui-Ping</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>4-4-24</u>	<u>Issuance</u>	<u>360,000,000</u>	<u>Common</u>	<u>0.0000</u> <u>1</u>	<u>Yes</u>	<u>Chien, Chin-Sheng</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>4-4-24</u>	<u>Issuance</u>	<u>360,000,000</u>	<u>Common</u>	<u>0.0000</u> <u>1</u>	<u>Yes</u>	<u>Chen, Yi-Ting</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>6-3-2025</u>	<u>Issuance</u>	<u>500,000</u>	<u>Common</u>	<u>0.0000</u> <u>1</u>	<u>Yes</u>	<u>Giles Duffield</u>	<u>Settlement of Debt</u>	<u>Restricted</u>	<u>144</u>
Shares Outstanding on Date of This Report: <u>Ending Balance:</u> Date <u>September 30, 2025</u> Common: <u>44,889,534,371</u> Preferred: <u>100,000</u>									

Example: A company with a fiscal year end of December 31st 2023, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2022 through December 31, 2023 pursuant to the tabular format above.

*****Control persons for any entities in the table above must be disclosed in the table or in a footnote here.**

Use the space below to provide any additional details, including footnotes to the table above:

B. Convertible Debt

The following is a complete list of the Company’s Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer’s equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

No: Yes: (If yes, you must complete the table below)

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion ⁶	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)

Total Outstanding Balance:

Total Shares:

*****Control persons for any entities in the table above must be disclosed in the table or in a footnote here.**

Use the space below to provide any additional details, including footnotes to the table above:

N/A

4) Issuer’s Business, Products and Services

The purpose of this section is to provide a clear description of the issuer’s current operations. Ensure that these descriptions are updated on the Company’s Profile on www.OTCMarkets.com.

⁶ The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any “blockers” or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

SAN GLOBAL DINING CO., LTD is a catering and catering management operation in Taiwan

- B. List any subsidiaries, parent company, or affiliated companies.

None

- C. Describe the issuers' principal products or services.

Catering Services

5) Issuer's Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

57F-1 No. 7, Sec 5 Xinyi Road
Xinyi District, Taipei, City
Taiwan, ROC

6) All Officers, Directors, and 5% Beneficial Owners of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities. If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, ≥ 5% beneficial owner)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
<u>San Global Dining Co. Ltd. -- Wang, Sung-Wei</u>	<u>Preferred Shareholder</u>	<u>Taipei City, Taiwan (R.O.C.)</u>	<u>100,000</u>	<u>Preferred Series A</u>	<u>100%</u>
<u>WANG, SUNG-WEI</u>	<u>Chairman of the Board, Director</u>	<u>Taoyuan City, Taiwan (R.O.C.)</u>	<u>16,200,000,000</u>	<u>Common</u>	<u>36.1%*</u>
<u>LIN, YI-KUAN</u>	<u>Director, CEO</u>	<u>Taipei City, Taiwan (R.O.C.)</u>	<u>8,100,000,000</u>	<u>Common</u>	<u>18.0%*</u>
<u>KUO, SHENG-MIN</u>	<u>Director, COO</u>	<u>Taipei City, Taiwan (R.O.C.)</u>	<u>8,100,000,000</u>	<u>Common</u>	<u>18.0%*</u>
<u>YA-FANG YU</u>	<u>CFO</u>	<u>Taipei City, Taiwan (R.O.C.)</u>	<u>0</u>	<u>---</u>	<u>---</u>

Confirm that the

information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

*These shares have been issued as of April 4, 2024 for their positions in the company

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

None

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such

person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

None

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

None

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

None

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

None

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel (must include Counsel preparing Attorney Letters).

Name: Barnett & Linn
Address 1: 60 Kavenish Drive
Address 2: Rancho Mirage, CA 92270
Phone: (442) 274-7571
Email: wbarnett@wbarnettlaw.com

Accountant or Auditor

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Investor Relations

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

All other means of Investor Communication:

X (Twitter): _____
Discord: _____
LinkedIn: _____
Facebook: _____
[Other]: _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: _____
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: YA-FANG YU
Title: Consultant
Relationship to Issuer: Consultant

B. The following financial statements were prepared in accordance with:

- IFRS
 U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: YA-FANG YU
Title: Consultant
Relationship to Issuer: Consultant

Describe the qualifications of the person or persons who prepared the financial statements:⁵
25 years accounting experience

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be “machine readable”. Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

⁵ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, YI-KUAN LIN certify that:

1. I have reviewed this Disclosure Statement for Plandai Biotechnology, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

November 19, 2025 [Date]

/s/ YI-KUAN LIN [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, YA-FANG YU certify that:

1. I have reviewed this Disclosure Statement for Plandai Biotechnology, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

November 19, 2025 [Date]

/s/ YA-FANG YU [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

PLANDAI BIOTECHNOLOGY, INC.
CONDENSED BALANCE SHEETS (UNAUDITED)

	September 30 2025	June 30 2025 (Restated)
ASSETS		
TOTAL ASSETS	\$ -	\$ -
LIABILITIES AND STOCKHOLDERS' DEFICIT		
Liabilities		
Current Liabilities		
Loans from Shareholders	\$ 72,195	\$ 57,446
Total Current Liabilities	72,195	57,446
Total Liabilities	72,195	57,446
Stockholders' Deficit		
Preferred Stock, Class A, Par \$0.0001, 100,000 shares authorized, 100,000 shares issued and outstanding as of September 30, 2025 and June 30, 2025, respectively	10	10
Common Stock, Par \$0.0001, 50 billion shares authorized, 44.89 billion shares issued and outstanding as of September 30, 2025 and June 30, 2025, respectively	4,488,953	4,488,953
Additional Paid-In Capital	35,878,955	35,878,955
Accumulated Deficit	(40,440,113)	(40,425,364)
Total Stockholder's Deficit	(72,195)	(57,446)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	\$ -	\$ -

The accompanying notes are an integral part of these financial statements.

PLANDAI BIOTECHNOLOGY, INC.
CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)

	Three Months Ended September 30	
	2025	2024
Revenues	\$ -	\$ -
Cost of Revenues	-	-
Gross Profit	-	-
Operating Expenses		
General and Administrative Expenses	188	-
Legal and Professional Expenses	14,561	3,780
Total Operating Expenses	14,749	3,780
Loss From Operations	(14,749)	(3,780)
Other Income (Expense)		
Total Other Income (Expense)	-	-
Net Income (Loss)	\$ (14,749)	\$ (3,780)
Net income (loss) per share attributable to common stockholders		
Basic & Diluted	\$ -	\$ -
Weighted average number of common shares outstanding		
Basic & Diluted	44,889,534,371	44,889,034,371

The accompanying notes are an integral part of these financial statements.

PLANDAI BIOTECHNOLOGY, INC.
CONDENSED STATEMENTS OF CHANGE IN STOCKHOLDERS' EQUITY (DEFICITS) (UNAUDITED)

	Class A Preferred Stock		Common Stock		Common Stock To Be Issued		Additional Paid-in Capital	Accumulated Earnings (Deficit)	Total Stockholders Equity
	Shares	Amount	Shares	Amount	Shares	Amount			
Balance at June 30, 2024 (Restated)	100,000	\$ 10	44,889,034,371	\$ 4,488,903	1,701,744,934	\$ 170,174	\$ 35,708,831	\$ (44,022,918)	\$ (55,000)
Net Loss	-	-	-	-	-	-	-	(3,780)	(3,780)
Balance at September 30, 2024 (Restated)	100,000	\$ 10	44,889,034,371	\$ 4,488,903	1,701,744,934	\$ 170,174	\$ 35,708,831	\$ (44,026,698)	\$ (58,780)
Balance at June 30, 2025 (Restated)	100,000	\$ 10	44,889,534,371	\$ 4,488,953	-	\$ -	\$ 35,878,955	\$ (40,425,364)	\$ (57,446)
Net Loss	-	-	-	-	-	-	-	(14,749)	(14,749)
Balance at September 30, 2025	100,000	\$ 10	44,889,534,371	\$ 4,488,953	-	\$ -	\$ 35,878,955	\$ (40,440,113)	\$ (72,195)

The accompanying notes are an integral part of these financial statements.

PLANDAI BIOTECHNOLOGY, INC.
STATEMENTS OF CASH FLOWS (UNAUDITED)

	September 30	
	2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES		
Net income	\$ (14,749)	\$ (3,780)
Net cash used in Operating Activities	(14,749)	(3,780)
CASH FLOWS FROM INVESTING ACTIVITIES		
Net cash provided by Investing Activities	-	-
CASH FLOWS FROM FINANCING ACTIVITIES		
Loans provided by Shareholders	14,749	3,780
Net cash provided by Financing Activities	14,749	3,780
NET CASH INCREASE FOR PERIOD		
	-	-
Cash at beginning of period	-	-
Cash at end of period	\$ -	\$ -
SUPPLEMENTAL CASH FLOW DISCLOSURES		
Cash paid for interest	\$ -	\$ -
Cash paid for income taxes	\$ -	\$ -

The accompanying notes are an integral part of these financial statements.

Plandai Biotechnology, Inc
Notes To Financial Statements (Unaudited)
For The Three Months Ended September 30, 2025 and 2024

NOTE 1 - ORGANIZATION AND OPERATIONS

Corporate History, Current Operations, and Business Plan

Plandai Biotechnology, Inc. ("Plandai", "PLPL" or the "Company"), incorporated in the State of Nevada on February 24, 2004 and moved to State of Wyoming on August 1, 2025, is a publicly quoted company. The Company operated as a shell company.

A Supplemental Information Report was filed as of March 9, 2023, and discloses a change in the shell status of the Company based on a pending share exchange agreement, which was cancelled in August 2023. After management's further review during the restatement of the annual report ended June 30, 2024 and 2025, the Company should have disclosed its status as a shell company upon the cancellation of the share exchange agreement. Therefore, the Company has been operating as a shell company since August 2023.

Changes of Control

In 2023, by virtue of a Binding Memorandum of Understanding with Good Salt, LLC, a Florida limited liability company ("Good Salt"). Plandai and Good Salt agreed to formalize a share exchange agreement whereby (i) Plandai would exchange restricted unregistered common shares, and separately, (ii) Plandai's majority shareholder would exchange Series "A" Preferred Common Stock with Good Salt, in exchange for (iii) all of the authorized and issued limited liability company interests of Good Salt.

On August 1, 2023, there was a rescission of the material definitive agreement with ByoPlant. The material definitive agreement, which was initially entered into on May 16, 2023, outlined the terms and conditions for the acquisition of the Company by Good Salt. However, despite diligent efforts and ongoing communications, conditions subsequent to the closing were unmet, and essential considerations were not settled. As a result, Plandai had no choice but to initiate the rescission process. The rescission will render the material definitive agreement null and void, and both parties will revert to their pre-agreement status.

On April 1, 2024, the Company's former controlling shareholders (the "Seller") closed the share purchase agreement with San Global and its controlling shareholders (collectively, the "Buyer"), pursuant the seller cancelled all the Company's debts (except for the convertible notes that is in process of cancellation), fulfilled other pre-close unsettled liabilities to third parties, and then transferred the control of the Company to the Buyer for the consideration of \$221,000. The transfer of the control is conducted by transferring the ownership of the Series A preferred stocks to the buyers, issuing 36 billion shares of new common stocks to the Buyer, and then success

the board to the Buyer. On June 17, 2025, the transfer of Series A preferred stocks is completed.

The Company's current operations are conducted at offices provided by San Global Dining Co. Ltd. ("San Global") without charge in Taipei, Taiwan. San Global is a holding company with various dining businesses in Taiwan.

PLPL does not have any ownership interest in the offices and there is no lease for the offices.

NOTE 2 - Restatement

The Company has restated its financial statements as of and for the year ended June 30, 2023, to correct misstatements in those prior periods related to improperly applying accounting guidance on FASB Accounting Standards Codification, or "ASC" no. 805, Business Combinations, regarding a share exchange transaction with ByoPlant in 2023, and ASC 505 Equity for the change of control with San Global in 2024.

As disclosed in Note 1, the Company had a binding share exchange agreement with ByoPlant and recorded the costs of the shares as "M&A Costs" of \$19,625,169 on the statement of operations for the year ended June 30, 2023, and corresponding amount to Common Stock to be issued \$3,925,034, Additional Paid-In Capital \$15,700,137 on the balance sheet as of June 30, 2023. Per new management's further review, such transaction was not closed by June 30, 2023, and then cancelled in August 2023. According to ASC 805, the share issuance to acquire a business should not be recognized as a cost to the statement of operations, but as an equity investment on the balance sheet. Further, since the transaction was not closed and no share was issued or exchanged, such transaction should not have been recognized. As a result, the Company reversed the M&A costs, stock to be issued, and additional paid-in capital amounts on its financial statements as of and for the year ended June 30, 2023 accordingly. The merger transaction was later cancelled in August 2023, and the related cancellation records are adjusted accordingly.

In April 2024, the Company issued 36 billion shares of common stocks for another change of control transaction. Since the issuance of common stock did not receive corresponding service or asset, no ASC 718 Compensation – Stock Compensation should be applied. In turn, ASC 505 Equity should be used to record the issuance of common stock in par value against additional paid-in capital. Related accounting records – Legal and professional expenses \$3,600,000 on the statement of operations for the year ended June 30, 2024 is adjusted as shown below. Certain equity account balances as of June 30, 2025 are adjusted accordingly.

Impacts of the Restatement – Year ended June 30, 2024

Balance Sheet

	June 30, 2024		
	As Reported	Adjustments	Restated
Investment in subsidiaries	\$ 100,000	\$ (100,000)	\$ -
Total Assets	100,000	(100,000)	-
Debenture payable	55,000	-	55,000
Loans from shareholders - Noncurrent	100,000	(100,000)	-
Total Liabilities	155,000	(100,000)	55,000
Preferred stock	10	-	10
Common stock	4,488,903	-	4,488,903
Common stock to be issued	170,174	-	170,174
Additional paid-in capital	39,308,831	(3,600,000)	35,708,831
Accumulated deficits	(44,022,918)	3,600,000	(40,422,918)
Total stockholders' equity (deficits)	(55,000)	-	(55,000)
Total Liabilities and Equity	\$ 100,000	\$ (100,000)	\$ -

Impacts of the Restatement – Year ended June 30, 2025

Balance Sheet

	June 30, 2025		
	As Reported	Adjustments	Restated
Investment in subsidiaries	\$ -	\$ -	\$ -
Total Assets	-	-	-
Debenture payable	-	-	-
Loans from shareholders - Noncurrent	57,446	-	57,446
Total Liabilities	57,446	-	57,446
Preferred stock	10	-	10
Common stock	4,488,953	-	4,488,953
Common stock to be issued	-	-	-
Additional paid-in capital	39,478,955	(3,600,000)	35,878,955
Accumulated deficits	(44,025,364)	3,600,000	(40,425,364)
Total stockholders' equity (deficits)	(57,446)	-	(57,446)
Total Liabilities and Equity	\$ -	\$ -	\$ -

No impacts to the statements of operations and cash flows for the year ended June 30, 2025.

NOTE 3 - GOING CONCERN

The accompanying financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the financial statements, the Company has incurred recurring net losses since its inception and has raised limited capital. These factors raise substantial doubt regarding the Company's ability to continue as a going concern. The financial statements do not include any adjustment relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company is taking certain steps to provide the necessary capital to continue its operations. These steps include but are not limited to: 1) focus on our new business model and 2) raising equity or debt financing. However, there can be no assurance that the Company will be successful in its efforts.

NOTE 4 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). The Company's fiscal yearend is June 30, and the Company's financial statements are expressed in U.S. dollars.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.

Fair Value Measurement

Pursuant to ASC Topic 820, Fair Value Measurements, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

- Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
- Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets: quoted prices for identical assets or liabilities in markets with

insufficient volume or infrequent transactions (less active markets); or model- derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

- Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

Stock-based Compensation

The Company has share-based compensation plans under which employees, consultants, suppliers, and directors may be granted restricted stock, as well as options and warrants to purchase shares of Company common stock at the fair market value at the time of grant. Stock-based compensation cost to employees is measured by the Company at the grant date, based on the fair value of the award, over the requisite service period under ASC 718. For options issued to employees, the Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit. Grants of stock to non-employees and other parties are accounted for in accordance with the ASC 718.

Basic Income (Loss) Per Share

Under the provisions of ASC 260, "Earnings per Share," basic loss per common share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income.

Segment Reporting

ASC 280 "Segment Reporting" requires public companies to report financial and descriptive information about their reportable operating segments. The Company identifies the operating segments based on how the chief operating decision maker internally evaluates separate financial information, business activities and management responsibility.

The Company currently has one reportable segment.

Recently Accounting Pronouncements

In November 2024, the FASB issued ASU No. 2024-03, Expense Disaggregation Disclosures (Subtopic 220-40). The ASU requires disclosure of specified information about certain costs and expenses. This includes purchases of inventory, employee compensation, depreciation, and intangible asset amortization. The ASU is effective on a prospective or retrospective basis for annual reporting period beginning after December 15, 2026, and interim reporting period beginning after December 15, 2027. Early adoption is permitted. This ASU will likely result in the required additional disclosures being included in its financial statements once adopted.

The Company has implemented all new accounting pronouncements that are in effect and that

may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

NOTE 5 – CONVERTIBLE NOTES

On December 24, 2024, Friend With Business (“FWB”) notified the Company that \$55,000 worth of the convertible notes, which FWB acquired from Adar Bays LLC in March 2024, was cancelled as part of transaction in transferring the control of the Company. As of September 30, 2025, there were no outstanding debts owed by the Company, except for the loans from the related party.

NOTE 6 – NOTE PAYABLE TO RELATED PARTIES

On December 31, 2015, the Company entered into a note payable with Dr. Giles Edward Duffield for \$52,500 that matured fifteen months from the date of payment of Consideration. The note is subject to 15% interest annually. As of December 31, 2023, \$43,500 of principal, and \$56,019 of interest remains outstanding. The Company is currently in default on this note. Per a Settlement Agreement drafted as of November 20, 2023, the Company has agreed to settle its debt with Dr. Giles Edward Duffield which the Company had entered into on December 31, 2015, at which time the Company entered into a note payable with Dr. Giles Edward Duffield for \$52,500 that matured fifteen months from the date of payment of Consideration. The note is subject to 15% interest annually. The settlement calls for the Company to provide Dr. Duffield with a cash payment of \$35,000 upon the subsequent closing of the anticipated sale of the Plandai corporate shell to a qualified buyer, the closing expected to occur within 30 days. The settlement also calls for Company to issue Dr. Duffield 500,000 shares of common stock. The Settlement Payment will be made within ten (10) days of the closing of the sale of Plandai, and the funds will be delivered to counsel for Duffield. The settlement agreement was closed and the 500,000 was issued in June 2025, pursuant to the note was satisfied and cancelled as of April 1, 2024 as part of the change of control agreement.

Loan from related parties is due to San Global, our controlling shareholder, and directors, for working capital purpose. Such loan bears no interest and due on demand.

NOTE 7 – PREFERRED STOCK

The Company is authorized to issue one class of preferred shares designated as “Series A Preferred Stock” in the amount of One Hundred Thousand (100,000) Shares with a par value of \$0.0001. The Company has 100,000 shares of Class A Preferred Stock issued and outstanding as of September 30, 2025, and June 30, 2025.

These Series A Preferred Shares shall not bear dividends.

Each Series A Preferred Shares is convertible to six hundred shares of the Company’s common

stock. The conversion can happen at any time on or after the earlier of (i) 30 days after the Issuance Date or (ii) the date that a registration statement covering the resale of Common Stock issued upon conversion of the Series A Preferred Share is declared effective by the Securities Exchange Commission (the SEC).

At every meeting of stockholders of the Company, the Series A Preferred Stock shall be entitled to voting rights equal, in aggregate, to the total number of then issued and outstanding shares eligible to vote on any manner, plus one additional vote.

In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, the holders of the Series A Preferred Shares shall be entitled to receive in cash out of the assets of the Company, whether from capital or from earnings available for distribution to its stockholders (the “Preferred Funds”), before any amount shall be paid to the holders of any of the capital stock of the Company of any class junior in rank to the Series A Preferred Shares in respect of the preferences as to the distributions and payments on the liquidation, dissolution, or winding up of the Company, an amount per Series A Preferred Shares equal to the Stated Value. All shares of Common Stock shall be of junior rank to all Series A Preferred Shares.

The Company completed the transfer of preferred shares to the new management on June 17, 2025.

NOTE 8 – COMMON STOCK

The Company has 50,000,000,000 shares of Common Stock authorized, and 44,889,534,371 and 44,889,534,371 shares of Common Stock issued and outstanding as of September 30, 2025, and June 30, 2025, respectively.

In June 2025, the Company issued 500,000 shares of its common stock to for previous debt settlement. See Note 5 for details.

NOTE 9 – RELATED PARTY TRANSACTIONS

The related parties of the company with whom transactions are reported in these financial statements are as follows:

Name of entity or Individual	Relationship with the Company and its subsidiaries
San Global Dining Co. Ltd. (“San Global”)	Entity controlled by controlling beneficiary shareholder of the Company
Directors	The Company’s new shareholders after transfer of control in April 2024

The Company’s directors and controlling shareholders have been paying for the Company’s operating expenses before the Company setting up the bank accounts. As of September 30, 2025 and June 30, 2025, due to related parties are amounted to \$88,874 and \$57,446, respectively.

NOTE 10 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events and transactions that occurred after September 30, 2025 up through the date the Company issued these financial statements. All subsequent events requiring recognition have been incorporated into these financial statements and there are no other subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events.”